Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
Pancreatic cancer (PCa) is one of the, if not the most difficult cancer diagnoses. According to the American Cancer Society, the average one year survival rate is 20% and the average five year survival rate is 7%. The Whipple surgical procedure is a pancreatic cancer survivor’s only real chance for a cure.
The main challenge with a diagnosis of pancreatic cancer is that approximately 80% of the time, PCa patients have cancers that have advanced too far for surgery to be possible. The study below speaks to the approximately 20% of those PCa patients who catch their cancer early enough to surgically remove it.
The study linked and excerpted below talks about neoadjuvant therapy for early stage PCa. Though the standard of care for early PCa is to undergo chemo after surgically removiing the pancreatic tumor, according to the article, about half of patients who have surgery are unable to undergo chemo. They experience complications from their surgery.
Further, the article may contain oncological jargon meaning phrases that average people don’t understand. One of the theoretical advantages of chemo before surgery is “downstaging of nodal disease,” This phrase means that preadjuvant chemotherapy may kill pancreatic cancer that has already spread beyond the tumor to the lymph nodes. It is the systemic spread of cancer that often causes a person’s cancer to relapse.
Two more therapies that are evidence-based but non-conventional. Pre-habilitation and Integrative Pancreatic cancer therapies. To learn more about pre-habilitation, please read the post highlighted in recommended reading below.
To learn more about therapies such as curcumin what research has shown can enhance the efficacy of conventional PCa chemo regimens such as gemcitabine/nab-paclitaxel, click now to go to the pancreatic cancer coaching program.
To learn more about pancreatic cancer, scroll down the page, post a question or a comment and I will reply to you ASAP.
“SEVERAL STUDIES presented at the 2019 Gastrointestinal Cancers Symposium evaluated the benefits of neoadjuvant treatment in patients with pancreatic cancer—and in patients deemed fully resectable, not just “borderline” resectable.1-3…
Although the standard of care for resectable pancreatic ductal adenocarcinoma remains surgery followed by adjuvant chemotherapy, approximately 50% of patients are unable to receive adjuvant treatment due to postoperative complications.
Neoadjuvant chemotherapy, it is believed, has several theoretical advantages, including
Prep-02/JSAP-05 demonstrated a significant survival benefit of neoadjuvant therapy, with a median overall survival of 36.7 months vs 26.6 months for upfront surgery.
Based on the superior outcomes, Dr. Unno commented: “We believe that neoadjuvant chemotherapy could be a new standard for patients with resectable pancreatic adenocarcinoma.”
Hematologic grade 3 or 4 adverse events, primarily leukopenia and neutropenia, were frequently observed in the neoadjuvant group…
Davendra Sohal, MD, MPH, of the Cleveland Clinic, reported that 29% of enrolled patients were found, on central review, not to have resectable disease.2
Patients received 12 weeks of neoadjuvant chemotherapy with either modified FOLFIRINOX or gemcitabine/nab-paclitaxel followed by surgical resection or 12 weeks of identical chemotherapy postoperatively. The primary outcome was 2-year overall survival. The investigators are also assessing differences in tolerability between the two regimens…